Quantum BioPharma Ltd.
QNTM
$18.09
$0.0350.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.89% | -18.09% | 25.49% | 3.67% | 6.49% |
| Depreciation & Amortization | 3.36% | 7.99% | -7.69% | -17.71% | -87.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.41% | 50.50% | 298.82% | 26.24% | -30.76% |
| Operating Income | -40.41% | -50.50% | -298.82% | -26.24% | 30.76% |
| Income Before Tax | -191.31% | -317.90% | -230.36% | -254.96% | 38.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -191.31% | -317.90% | -230.36% | -254.96% | 38.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 113.34% | -13.24% | -62.65% | 163.59% | -- |
| Net Income | -197.35% | -350.60% | -284.39% | -261.12% | 43.32% |
| EBIT | -40.41% | -50.50% | -298.82% | -26.24% | 30.76% |
| EBITDA | -41.94% | -52.90% | -324.79% | -28.28% | 14.54% |
| EPS Basic | 36.89% | -11.07% | -17.46% | -137.22% | 46.64% |
| Normalized Basic EPS | 36.76% | -20.44% | -104.79% | 19.24% | 37.61% |
| EPS Diluted | 36.89% | -11.07% | -17.46% | -137.22% | 46.66% |
| Normalized Diluted EPS | 36.76% | -20.44% | -104.79% | 19.24% | 37.61% |
| Average Basic Shares Outstanding | 371.15% | 305.74% | 227.25% | 52.21% | 6.23% |
| Average Diluted Shares Outstanding | 371.15% | 305.74% | 227.25% | 52.21% | 6.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |